secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0001558370-24-012783
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus warns of temporary UDENYCA supply interruption due to packaging CMO constraints
--------------------------------------------------------------------------------

- Third-party CMO over-commitments cause labeling/packaging delay; API and drug product unaffected.
- Channel supply projected depleted by mid-Oct; manufacturing to resume mid-Oct, product availability early Nov.
- Company secures second packaging CMO; commercial supply expected Q1 2025, more than doubling capacity.
- Since 2021, invested >$30M across supply chain; expects UDENYCA production cost to drop ~1/3 from current levels.
- Reaffirms combined 2024 R&D and SG&A expense guidance of $250-265M, including ~$40M stock-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024012783/0001558370-24-012783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024012783/chrs-20240913x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer